Condensed Consolidated Interim Financial Statements as of March 31, 2017

Bayer Group
Consolidated Income Statements

 

 

Q1 2016

 

Q1 2017

 

 

€ million

 

€ million

2016 figures restated

1

For definition see Annual Report 2016, Chapter “Alternative Performance Measures Used by the Bayer Group.”

Net sales

 

11,854

 

13,244

Cost of goods sold

 

(5,044)

 

(5,345)

Gross profit

 

6,810

 

7,899

Selling expenses

 

(2,888)

 

(3,013)

Research and development expenses

 

(1,109)

 

(1,158)

General administration expenses

 

(495)

 

(572)

Other operating income

 

203

 

175

Other operating expenses

 

(201)

 

(215)

EBIT1

 

2,320

 

3,116

Equity-method loss

 

(5)

 

(13)

Financial income

 

37

 

35

Financial expenses

 

(347)

 

(371)

Financial result

 

(315)

 

(349)

Income before income taxes

 

2,005

 

2,767

Income taxes

 

(474)

 

(595)

Income from continuing operations after income taxes

 

1,531

 

2,172

Income from discontinued operations after income taxes

 

50

 

99

Income after income taxes

 

1,581

 

2,271

of which attributable to noncontrolling interest

 

70

 

188

of which attributable to Bayer AG stockholders (net income)

 

1,511

 

2,083

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

From continuing operations

 

 

 

 

Basic

 

1.77

 

2.28

Diluted

 

1.77

 

2.28

From discontinued operations

 

 

 

 

Basic

 

0.06

 

0.11

Diluted

 

0.06

 

0.11

From continuing and discontinued operations

 

 

 

 

Basic

 

1.83

 

2.39

Diluted

 

1.83

 

2.39